跳到正文
MHRA 药品召回与缺陷通报·· 11 天前AI 评分48

MHRA第4类药品缺陷通报:Star Pharmaceuticals Ltd 依那普利马来酸盐/氢氯噻嗪20 mg/12.5 mg片剂(EL(26)A/48)

Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48

AI 导读

MHRA发布第4类药品缺陷通报,Star Pharmaceuticals Ltd的依那普利马来酸盐/氢氯噻嗪20 mg/12.5 mg片剂因纸盒正面氢氯噻嗪规格误印为“12. mg”(应为“12.5 mg”)被通报,涉及Y018198、Y019635、C125483、C135541四个批次,英国市场共1740盒。药片质量不受影响,风险判定为低,医护人员应继续调配并向患者说明。

正文 · 原文

Contents

  1. DMRC reference number
  2. Marketing Authorisation Holder
  3. Medicine Details
    1. Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets
  4. Affected Lot Batch Numbers
  5. Background
  6. Advice for Healthcare Professionals
  7. Advice for Healthcare Professionals to Provide to Patients
  8. Additional information
  9. Download document

DMRC reference number

DMRC-41407584

Marketing Authorisation Holder

Star Pharmaceuticals Ltd

Medicine Details

Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets

PLPI: 20636/1651

Active ingredient: enalapril maleate / hydrochlorothiazide

GTIN: 05050114165107

Affected Lot Batch Numbers

Batch No. Expiry Date Pack Size First Distributed
Y018198 30/06/2027 28 22/09/2026
Y019635 31/10/2027 28 05/12/2025
C125483 29/02/2028 28 05/03/2026
C135541 30/11/2028 28 08/06/2026

Background

Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead of “12.5 mg”. The strength is correctly presented on all other faces of the carton, the leaflet and the blister foil. The volume of affected stock distributed to the UK market is 1740 packs.

Advice for Healthcare Professionals:

Healthcare professionals are asked to note the information in this notification and should continue to dispense this product; the quality of the tablets is not impacted by this labelling defect.

The risk associated with the labelling error is considered low because no corresponding strengths of the enalapril maleate / hydrochlorothiazide combination where the hydrochlorothiazide strength is expressed as 12 mg exist.

Healthcare professionals are advised to reassure patients, if contacted, that the product is enalapril maleate 20 mg / hydrochlorothiazide 12.5 mg tablets as described in the Patient Information Leaflet.

Advice for Healthcare Professionals to Provide to Patients:

Patients should continue to take this medication as prescribed. This does not affect the quality of the tablets.

If you are unsure or have any questions, please seek advice from your pharmacy or other healthcare professionals involved in your treatment.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information:

For all medical information enquiries and information on this product, please email info@drugsrus.co.uk or telephone 020 8423 2111.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre

10 South Colonnade

Canary Wharf

London

E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk

Download document

Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48

来源:MHRA 药品召回与缺陷通报 · gov.uk